Basic Information
| LncRNA/CircRNA Name | SNHG12 |
| Synonyms | SNHG12, ASLNC04080, C1orf79, LINC00100, NCRNA00100, PNAS-123 |
| Region | GRCh38_1:28578538-28582983 |
| Ensemble | ENSG00000197989 |
| Refseq | NR_024127 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot |
| Sample | NSCLiver Cancer tissue, NSCLiver Cancer cell line (A549 )and DDP-resistant cell line A549/DDP |
| Expression Pattern | up-regulated |
| Function Description | Overall, our study is the first to identify a SNHG12-miR-181a-MAPK/Slug axis to elucidate in part how SNHG12 exert functions in NSCLC MDR, providing a novel therapeutic target to overcome MDR in NSCLC. |
| Pubmed ID | 29137407 |
| Year | 2017 |
| Title | LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. |
External Links
| Links for SNHG12 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |